{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:08:18Z","timestamp":1790150898574,"version":"4.0.1"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":244,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Re-irradiation (re-RT) has gained popularity in the treatment of recurrent or progressive glioblastoma (rGBM) after first-line treatment. However, uncertainties regarding optimal treatment dose, fraction size and target volume definition remain. In this multicenter analysis of the Western German Cancer Center (WTZ), we analyze prognostic factors for patients treated with re-RT for rGBM with different fraction regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed patients with rGBM (CNS-WHO \u00b04, IDH-wildtype) who received re-RT after standard first-line treatment (\u00b1salvage resection\/chemotherapy) between 01\/2010 and 12\/2021. Clinical, histopathological, and radiological data were evaluated to identify prognostic factors influencing event-free and overall survival, as well as treatment tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 118 patients, of whom 87 received normofractionated (1.8-2 Gy\/fx) re-RT with a mean dose of 40.8 Gy using a mean gross tumor volume-planning target volume (GT-PTV) margin of 8.8 mm. 31 patients were treated with moderate hypofractionation (2.4-3.5 Gy\/fx) up to a mean dose of 36 Gy with a mean GTV-PTV margin of 4.1 mm. Propensity score weighting was used to compensate prognostic factors between these 2 cohorts. Re-resection classification (no, STR, GTR, P\u2009&amp;lt;\u2009.0001), age at diagnosis (P\u2009=\u2009.0082), unifocal vs. multifocal progression (P\u2009=\u2009.021), and time between first and second RT (P\u2009=\u2009.0109) were identified as significant prognostic factors using stepwise parameter selection. The propensity score weighted survival was 8.8 months for normofractionation and 9.9 months for hypofractionation (P\u2009=\u2009.63).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Age at initial diagnosis, progression pattern, and time between first and second RT are prognostic for patients undergoing re-RT. No significant survival difference between normofractionated and hypofractionated approaches was detected, which should be further investigated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag231","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:51:25Z","timestamp":1788353485000},"source":"Crossref","is-referenced-by-count":0,"title":["A multicenter analysis of prognostic factors for patients undergoing re-irradiation for recurrent glioblastoma"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5917-4203","authenticated-orcid":false,"given":"Niklas Benedikt","family":"Pepper","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University Hospital M\u00fcnster , M\u00fcnster,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Guberina","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Essen , Essen,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site Essen\/D\u00fcsseldorf, A Partnership between DKFZ and University Hospital Essen , Essen,","place":["Germany"]},{"name":"DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), University Medicine Essen, University Duisburg-Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9224-9318","authenticated-orcid":false,"given":"Christoph","family":"P\u00f6ttgen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian Martin","family":"Troschel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital M\u00fcnster , M\u00fcnster,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oertel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital M\u00fcnster , M\u00fcnster,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Fischedick","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Oliver","family":"Kiwitt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9262-7289","authenticated-orcid":false,"given":"Cornelius","family":"Deuschl","sequence":"additional","affiliation":[{"name":"Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan","family":"Jabbarli","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9073-1821","authenticated-orcid":false,"given":"Ulrich","family":"Sure","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Dammann","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Wrede","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0678-5852","authenticated-orcid":false,"given":"Sied","family":"Kebir","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Partner Site Essen\/D\u00fcsseldorf, A Partnership between DKFZ and University Hospital Essen , Essen,","place":["Germany"]},{"name":"DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), University Medicine Essen, University Duisburg-Essen , Essen,","place":["Germany"]},{"name":"Department of Neurology, University Hospital Essen , Essen,","place":["Germany"]},{"name":"Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Junker","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, University Hospital Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-5555","authenticated-orcid":false,"given":"Michael","family":"M\u00fcther","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital M\u00fcnster , M\u00fcnster,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8316-6556","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Scheffler","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Partner Site Essen\/D\u00fcsseldorf, A Partnership between DKFZ and University Hospital Essen , Essen,","place":["Germany"]},{"name":"DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), University Medicine Essen, University Duisburg-Essen , Essen,","place":["Germany"]},{"name":"Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Grauer","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital M\u00fcnster , M\u00fcnster,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Kuhlmann","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, University Hospital M\u00fcnster , M\u00fcnster,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9103-2357","authenticated-orcid":false,"given":"Walter","family":"Stummer","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital M\u00fcnster , M\u00fcnster,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Padeberg","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Theodor","family":"Eich","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital M\u00fcnster , M\u00fcnster,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika","family":"Guberina","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Partner Site Essen\/D\u00fcsseldorf, A Partnership between DKFZ and University Hospital Essen , Essen,","place":["Germany"]},{"name":"DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), University Medicine Essen, University Duisburg-Essen , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"2026092303370553600_vdag231-B1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","article-title":"Current status and recent advances in reirradiation of glioblastoma","volume":"16","author":"Minniti","year":"2021","journal-title":"Radiat Oncol"},{"key":"2026092303370553600_vdag231-B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","article-title":"NCCN guidelines\u00ae insights: central nervous system cancers, version 2.2022: featured updates to the NCCN guidelines","volume":"21","author":"Horbinski","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"2026092303370553600_vdag231-B3","doi-asserted-by":"publisher","first-page":"103923","DOI":"10.1016\/j.bas.2024.103923","article-title":"Recurrent glioblastoma in national guidelines on the diagnosis and treatment of gliomas: a matter of European practice variation","volume":"4","author":"Van Opijnen","year":"2024","journal-title":"Brain Spine"},{"key":"2026092303370553600_vdag231-B4","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1093\/neuonc\/noaf177","article-title":"Glioblastoma in adults: a society for neuro-oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026092303370553600_vdag231-B5","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.3390\/cancers15112982","article-title":"Location of recurrences after trimodality treatment for glioblastoma with respect to the delivered radiation dose distribution and its influence on prognosis","volume":"15","author":"Guberina","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026092303370553600_vdag231-B6","doi-asserted-by":"publisher","first-page":"109600","DOI":"10.1016\/j.radonc.2023.109600","article-title":"Recurrence analysis of glioblastoma cases based on distance and dose information","volume":"183","author":"Langhans","year":"2023","journal-title":"Radiotherapy and Oncology"},{"key":"2026092303370553600_vdag231-B7","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/neuonc\/noy020","article-title":"Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the glioma longitudinal analysis consortium","volume":"20","author":"Aldape","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026092303370553600_vdag231-B8","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG oncology\/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026092303370553600_vdag231-B9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s13063-024-08213-7","article-title":"Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study","volume":"25","author":"Preusser","year":"2024","journal-title":"Trials"},{"key":"2026092303370553600_vdag231-B10","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.ijrobp.2024.07.216","article-title":"Target volume delineation for the re-irradiation of recurrent glioblastoma: MRI- or PET-based? Results of the GLIAA prospective randomized trial","volume":"120","author":"Popp","year":"2024","journal-title":"Int J Radiat Oncol *Biol *Phys"},{"key":"2026092303370553600_vdag231-B11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12885-017-3928-7","article-title":"Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma\u2014the GlioCave study (NOA 17\u2014ARO 2016\/3\u2014DKTK ROG trial)","volume":"18","author":"Straube","year":"2018","journal-title":"BMC Cancer"},{"key":"2026092303370553600_vdag231-B12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(25)00642-4","article-title":"O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA\/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial","volume":"27","author":"Grosu","year":"2026","journal-title":"Lancet Oncol"},{"key":"2026092303370553600_vdag231-B13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00066-009-1753-x","article-title":"Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy?","volume":"185","author":"Fokas","year":"2009","journal-title":"Strahlenther Onkol"},{"key":"2026092303370553600_vdag231-B14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s11060-010-0446-8","article-title":"Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma","volume":"103","author":"Minniti","year":"2011","journal-title":"J Neurooncol"},{"key":"2026092303370553600_vdag231-B15","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.adro.2020.06.005","article-title":"Reirradiation of high-grade gliomas: a retrospective analysis of 198 patients based on the Charit\u00e9 data set","volume":"5","author":"Kaul","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"2026092303370553600_vdag231-B16","doi-asserted-by":"publisher","first-page":"109947","DOI":"10.1016\/j.radonc.2023.109947","article-title":"Re-irradiation in clinical practice: results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform","volume":"189","author":"Willmann","year":"2023","journal-title":"Radiother Oncol"},{"key":"2026092303370553600_vdag231-B17","doi-asserted-by":"publisher","first-page":"102029","DOI":"10.1016\/j.ctrv.2020.102029","article-title":"How did lomustine become standard of care in recurrent glioblastoma?","volume":"87","author":"Weller","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2026092303370553600_vdag231-B18","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol *Biol *Phys"},{"key":"2026092303370553600_vdag231-B19","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/jnci\/djq393","article-title":"Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data","volume":"102","author":"Hadley","year":"2010","journal-title":"JNCI"},{"key":"2026092303370553600_vdag231-B20","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1214\/aos\/1013699998","article-title":"The control of the false discovery rate in multiple testing under dependency","volume":"29","author":"Benjamini","year":"2001","journal-title":"Ann Statist"},{"key":"2026092303370553600_vdag231-B21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/BF01068419","article-title":"A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability","volume":"15","author":"Schuirmann","year":"1987","journal-title":"J Pharmacokinet Biopharm"},{"key":"2026092303370553600_vdag231-B22","author":"Wick","year":"2021"},{"key":"2026092303370553600_vdag231-B23","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ijrobp.2021.12.152","article-title":"The impact of tumor treating fields on glioblastoma progression patterns","volume":"112","author":"Glas","year":"2022","journal-title":"Int J Radiat Oncol *Biol *Phys"},{"key":"2026092303370553600_vdag231-B24","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/neuonc\/noad074","article-title":"Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: a report of the RANO resect group","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026092303370553600_vdag231-B25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11060-004-2463-y","article-title":"Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme","volume":"74","author":"Combs","year":"2005","journal-title":"J Neurooncol"},{"key":"2026092303370553600_vdag231-B26","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.3390\/cancers16213652","article-title":"Efficacy and low toxicity of\u00a0normo-fractionated re-irradiation with combined chemotherapy for recurrent glioblastoma\u2014an analysis of treatment response and failure","volume":"16","author":"Pepper","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026092303370553600_vdag231-B27","doi-asserted-by":"publisher","first-page":"8863","DOI":"10.1200\/JCO.2005.03.4157","article-title":"Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution","volume":"23","author":"Combs","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026092303370553600_vdag231-B28","doi-asserted-by":"publisher","first-page":"6304","DOI":"10.1158\/1078-0432.CCR-14-0951-T","article-title":"A phase II, randomized, study of weekly APG101\u2009+\u2009reirradiation versus reirradiation in progressive glioblastoma","volume":"20","author":"Wick","year":"2014","journal-title":"Clinical Cancer Research"},{"key":"2026092303370553600_vdag231-B29","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11060-016-2267-x","article-title":"Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma","volume":"130","author":"Schnell","year":"2016","journal-title":"J Neurooncol"},{"key":"2026092303370553600_vdag231-B30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.radonc.2019.06.009","article-title":"Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma","volume":"138","author":"Fleischmann","year":"2019","journal-title":"Radiother Oncol"},{"key":"2026092303370553600_vdag231-B31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11060-014-1394-5","article-title":"Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option","volume":"117","author":"Flieger","year":"2014","journal-title":"J Neurooncol"},{"key":"2026092303370553600_vdag231-B32","doi-asserted-by":"publisher","first-page":"110624","DOI":"10.1016\/j.radonc.2024.110624","article-title":"Ongoing prospective studies on reirradiation: a systematic review of a clinical trials database","volume":"202","author":"Willmann","year":"2025","journal-title":"Radiother Oncol"},{"key":"2026092303370553600_vdag231-B33","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1200\/JCO.2014.55.1143","article-title":"Role of radiation therapy in palliative care of the patient with cancer","volume":"32","author":"Lutz","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026092303370553600_vdag231-B34","doi-asserted-by":"publisher","first-page":"846","DOI":"10.21037\/apm-20-1246","article-title":"Narrative review of palliative hypofractionated radiotherapy for high grade glioma","volume":"10","author":"Saeed","year":"2021","journal-title":"Ann Palliat Med"},{"key":"2026092303370553600_vdag231-B35","doi-asserted-by":"publisher","first-page":"101029","DOI":"10.1016\/j.ctro.2025.101029","article-title":"Reirradiation of recurrent glioblastoma: results from a single-center retrospective cohort study","volume":"55","author":"Dejonckheere","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"key":"2026092303370553600_vdag231-B36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11060-014-1524-0","article-title":"Hypofractionated stereotactic reirradiation for recurrent glioblastoma","volume":"120","author":"Yazici","year":"2014","journal-title":"J Neurooncol"},{"key":"2026092303370553600_vdag231-B37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ijrobp.2005.01.056","article-title":"Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)\/CT\/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy","volume":"63","author":"Grosu","year":"2005","journal-title":"Int J Radiat Oncol *Biol *Phys"},{"key":"2026092303370553600_vdag231-B38","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","article-title":"Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas","volume":"28","author":"Fogh","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026092303370553600_vdag231-B39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11060-012-0999-9","article-title":"Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas","volume":"111","author":"Minniti","year":"2013","journal-title":"J Neurooncol"},{"key":"2026092303370553600_vdag231-B40","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.ijrobp.2025.08.031","article-title":"Efficacy of hypofractionated stereotactic radiotherapy with different dose fractionation regimens combined with concurrent bevacizumab in recurrent high-grade gliomas: a randomized controlled trial","volume":"123","author":"Liu","year":"2025","journal-title":"Int J Radiat Oncol *Biol *Phys"},{"key":"2026092303370553600_vdag231-B41","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1016\/j.wneu.2020.02.005","article-title":"Analysis of a surgical series of 21 cerebral radiation necroses","volume":"137","author":"Campos","year":"2020","journal-title":"World Neurosurgery."},{"key":"2026092303370553600_vdag231-B42","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00066-022-01973-8","article-title":"DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment","volume":"198","author":"Bernhardt","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"2026092303370553600_vdag231-B43","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00066-022-01994-3","article-title":"DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis","volume":"198","author":"Bernhardt","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"2026092303370553600_vdag231-B44","doi-asserted-by":"publisher","first-page":"110437","DOI":"10.1016\/j.radonc.2024.110437","article-title":"Re-irradiation treatment regimens for patients with recurrent glioma\u2014evaluation of the optimal dose and best concurrent therapy","volume":"199","author":"Fleischmann","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026092303370553600_vdag231-B45","doi-asserted-by":"publisher","first-page":"111030","DOI":"10.1016\/j.radonc.2025.111030","article-title":"Reirradiation dose constraints in clinical practice: results of an international survey","volume":"210","author":"Stroom","year":"2025","journal-title":"Radiother Oncol"},{"key":"2026092303370553600_vdag231-B46","doi-asserted-by":"publisher","first-page":"110696","DOI":"10.1016\/j.radonc.2024.110696","article-title":"ESTRO\/EANO recommendation on reirradiation of glioblastoma","volume":"204","author":"Andratschke","year":"2025","journal-title":"Radiother Oncol"},{"key":"2026092303370553600_vdag231-B47","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/cam4.1425","article-title":"Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score\u2014report of the radiation oncology group (ROG) of the German cancer consortium (DKTK)","volume":"7","author":"Combs","year":"2018","journal-title":"Cancer Med"},{"key":"2026092303370553600_vdag231-B48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.radonc.2018.01.011","article-title":"Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: a multicenter DKTK\/ROG analysis","volume":"127","author":"Niyazi","year":"2018","journal-title":"Radiother Oncol"},{"key":"2026092303370553600_vdag231-B49","doi-asserted-by":"publisher","first-page":"e0180457","DOI":"10.1371\/journal.pone.0180457","article-title":"Modification and optimization of an established prognostic score after re-irradiation of recurrent glioma","volume":"12","author":"Kessel","year":"2017","journal-title":"PLoS One"},{"key":"2026092303370553600_vdag231-B50","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s00066-024-02359-8","article-title":"Multidisciplinary treatment is necessary in glioblastoma with extracerebral metastases","volume":"201","author":"Pepper","year":"2025","journal-title":"Strahlenther Onkol"},{"key":"2026092303370553600_vdag231-B51","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026092303370553600_vdag231-B52","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA\u201309): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag231\/70922662\/vdag231.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag231\/70922662\/vdag231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag231\/70922662\/vdag231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:37:12Z","timestamp":1790149032000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag231\/8779994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag231","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag231"}}